The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA approves brentuximab vedotin with combination chemotherapy for advanced stage classical HL
On 20 March 2018, the US Food and Drug Administration (FDA) granted approval of brentuximab vedotin in combination with chemotherapy, for the treatment of adults with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).
The FDA approval was based on the successful results from the multicenter, open-label, randomized ECHELON-1 phase III clinical trial (NCT01712490). In this study, brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (A+AVD) was compared to AVD plus bleomycin (ABVD), as a regimen for advanced stage cHL patients. Superior efficacy of A+AVD was reported with a significantly lower combined risk of progression, as compared to ABVD.
The FDA had granted this application Priority Review and Breakthrough Therapy designation. According to Richard Pazdur, Director of the FDA Oncology Center of Excellence “Today’s approval represents an improvement in the initial treatment regimens of advanced HL that were introduced into clinical practice more than 40 years ago”.
In an interview we conducted at ASH 2017, Atlanta, GA, Professor Anas Younes from the Weill-Cornell Medical College, discussed the ECHELON-1 results and how they impact the current standard of care for advanced-stage HL patients.
References